All Blogs

Feb 21, 2019

Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer, has raised USD 150 million. Peloton’s lead therapeutic candidate, PT2977, focuses on targeting hypoxia-inducible fac...

Feb 20, 2019

The ability of CRISPR to change an organism’s DNA has lead researchers, particularly from Nigeria to use the tool to perform diagnostic tests. Since CRISPR therapeutics is all about targeting the genome-specific sequence, the test is believed to pinpoint the exact viral strain circulating. The recent epidemi...

Feb 19, 2019

CRISPR treatment delivers benefits in mice The researchers from Duke University along with drugmaker Sarepta Therapeutics published a report stating that a single change in the genetic system of Duchenne muscular dystrophy (DMD) affected mice, using CRISPR gene editing tool resulted in increasing their life spa...

Feb 18, 2019

Diabetes – a chronic condition in which sugar is not processed in the body. Diabetic people either do not produce enough insulin or cells halt responding to insulin. Due to this, sugar keeps on accumulating in the blood that leads to increased sugar. Gradually, high blood sugar can lead to nerve damage and heart di...

Feb 14, 2019

Neurogene raises USD 68.5 Million for rare neurological diseases Neurogene netted USD 68.5 million to advance multiple gene therapy programs in its series A round. The idea is to take its major programs into IND-enabling studies for Aspartylglucosaminuria (AGU) and a rare form of Charcot-Marie Tooth disease with...

Feb 13, 2019

The hallucinogenic party drug, ketamine has passed the final problem for going into the clinical stage as an antidepressant. The US Food and Drug Administration (FDA), an independent advisory committee, supported in favour of commending a compound known as esketamine, used for treating depression. If the FDA giv...

Feb 12, 2019

The nasal antidepressant of Johnson & Johnson leads to FDA committee The antidepressant esketamine of Johnson & Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies for the disorder. The intranasal, esketamine would be one of the first new approaches to treat the refrac...

Feb 11, 2019

Raynaud's Disease (RD), also called Raynaud's phenomenon, is a rare disorder of the blood vessels. The symptoms include when one is feeling cold or feeling stressed in some areas of the body like fingers and toes, blood can't reach to the epidermis (surface of the skin) and the affected areas turn wh...

Feb 08, 2019

https://www.slideshare.net/DelveInsight/acromegaly-and-gigantism-therapeutics-2?qid=ed224bb4-073c-4c5a-acdc-a02b6bad09d7&v=&b=&from_search=6 Acromegaly :-The excessive Growth Hormone comes from benign tumors on the pituitary. It is rare but serious hormonal disorder.

Feb 07, 2019

Genentech remunerates Xencor USD 120 Million for global rights Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor. Xencor is pursuing IL-15, an immune signaling protein, contemplating that it can stimulate natural...